Tuned activation of MSLN-CAR T cells induces superior antitumor responses in ovarian cancer models.
Esther SchoutropThomas PoiretIbrahim El-SerafiYing ZhaoRui HeAlina MoterJohan HenrikssonMoustapha HassanIsabelle MagalhaesJonas MattssonPublished in: Journal for immunotherapy of cancer (2023)
Altogether, our study demonstrates the enhanced therapeutic potential of MSLN-CAR T cells expressing a mutated CD3ζ chain containing a single ITAM for the treatment of ovarian cancer. CAR T cells armored with calibrated activation potential may improve the clinical responses in solid tumors.
Keyphrases